Business Description
Harmony Biosciences Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US4131971040
Share Class Description:
HRMY: Ordinary SharesTotal Employee Number:
293Description
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.34 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.55 | |||||
Interest Coverage | 17.12 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.67 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 27.4 | |||||
3-Year EBITDA Growth Rate | 21.9 | |||||
3-Year EPS without NRI Growth Rate | 6.3 | |||||
3-Year FCF Growth Rate | 36 | |||||
3-Year Book Growth Rate | 30.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.45 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.91 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.18 | |||||
9-Day RSI | 64.84 | |||||
14-Day RSI | 61.59 | |||||
3-1 Month Momentum % | 12.9 | |||||
6-1 Month Momentum % | -0.7 | |||||
12-1 Month Momentum % | 6.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.48 | |||||
Quick Ratio | 3.45 | |||||
Cash Ratio | 2.85 | |||||
Days Inventory | 9.28 | |||||
Days Sales Outstanding | 38.76 | |||||
Days Payable | 37.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 0.73 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.42 | |||||
Operating Margin % | 24.03 | |||||
Net Margin % | 18.88 | |||||
EBITDA Margin % | 29.17 | |||||
FCF Margin % | 36.97 | |||||
OCF Margin % | 36.99 | |||||
ROE % | 20.66 | |||||
ROA % | 14.54 | |||||
ROIC % | 36.16 | |||||
3-Year ROIIC % | 28.21 | |||||
ROC (Joel Greenblatt) % | 18216.95 | |||||
ROCE % | 24.84 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.58 | |||||
Forward PE Ratio | 10.35 | |||||
PE Ratio without NRI | 11.85 | |||||
Price-to-Owner-Earnings | 8.72 | |||||
PEG Ratio | 0.11 | |||||
PS Ratio | 2.4 | |||||
PB Ratio | 2.25 | |||||
Price-to-Tangible-Book | 2.44 | |||||
Price-to-Free-Cash-Flow | 6.38 | |||||
Price-to-Operating-Cash-Flow | 6.38 | |||||
EV-to-EBIT | 6.84 | |||||
EV-to-Forward-EBIT | 2.64 | |||||
EV-to-EBITDA | 6.22 | |||||
EV-to-Forward-EBITDA | 6.06 | |||||
EV-to-Revenue | 1.82 | |||||
EV-to-Forward-Revenue | 1.66 | |||||
EV-to-FCF | 4.91 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 0.68 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.47 | |||||
Price-to-Graham-Number | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 5.11 | |||||
| Price-to-Net-Cash | 7.66 | |||||
Earnings Yield (Greenblatt) % | 14.62 | |||||
FCF Yield % | 15.73 | |||||
Forward Rate of Return (Yacktman) % | 29.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HRMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harmony Biosciences Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 959.898 | ||
| EPS (TTM) ($) | 3.08 | ||
| Beta | 1.4327 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 48.07 | ||
| 14-Day RSI | 61.59 | ||
| 14-Day ATR ($) | 1.620787 | ||
| 20-Day SMA ($) | 35.76375 | ||
| 12-1 Month Momentum % | 6.75 | ||
| 52-Week Range ($) | 25.52 - 40.87 | ||
| Shares Outstanding (Mil) | 58.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harmony Biosciences Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harmony Biosciences Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 91 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 90 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | 38.78 (+4.53%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 38.78 (+4.53%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:30 | 35.60 (-0.53%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 35.60 (-0.53%) | ||
| Oppenheimer CNS & Neuro-Muscular Summit | 2026-06-10 15:25 | 34.10 (+4.09%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:40 | 32.39 (+0.09%) | ||
| General meeting for 2026 | 2026-05-15 13:00 | 30.76 (-0.65%) | ||
| General meeting for 2026 | 2026-05-14 13:00 | 30.83 (+2.73%) |
Show
Entries
Harmony Biosciences Holdings Inc Frequently Asked Questions
What is Harmony Biosciences Holdings Inc(HRMY)'s stock price today?
The current price of HRMY is $38.74. The 52 week high of HRMY is $40.87 and 52 week low is $25.52.
When is next earnings date of Harmony Biosciences Holdings Inc(HRMY)?
The next earnings date of Harmony Biosciences Holdings Inc(HRMY) is 2026-11-04 Est..
Does Harmony Biosciences Holdings Inc(HRMY) pay dividends? If so, how much?
Harmony Biosciences Holdings Inc(HRMY) does not pay dividend.
Guru Commentaries on NAS:HRMY
No articles.
Press Release
Articles on Harmony Biosciences Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers